ORIC presents research on rinzimetostat, an allosteric PRC2 inhibitor combined with darolutamide, in a Phase 3 study for patients with metastatic castration-resistant prostate cancer.
Rich Heyman, PhD will transition from interim CEO to Chairman of the ORIC Board of Directors South San Francisco, CA – May 7, 2018 – ORIC Pharmaceuticals, a clinical-stage oncology company focused on discovery and development of novel therapies against treatment-resistant cancers, announced today
South San Francisco, CA – March 9, 2015 – ORIC Pharmaceuticals, Inc., a privately-held company dedicated to the discovery and development of novel therapeutics for the treatment of cancer, announced today that Richard Heyman, Ph.D. will be joining its Board of Directors. Dr.
South San Francisco, CA – March 9, 2015 – ORIC Pharmaceuticals, Inc., a privately-held company dedicated to the discovery and development of novel therapeutics for the treatment of cancer, announced today that Richard Scheller, Ph.D. will be joining its Board of Directors. Dr.
Proceeds will support advancement of ORIC-101 against treatment-resistant solid tumors and continued progress on mechanisms of resistance in cancer Lead program ORIC-101 is expected to enter trials with oncology patients in 2018 South San Francisco, CA – February 21, 2018 – ORIC
